AVEO Pharmaceuticals, Inc.
AVEO
AVEO was delisted on the 19th of January, 2023.
101 hedge funds and large institutions have $166M invested in AVEO Pharmaceuticals, Inc. in 2018 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 36 increasing their positions, 16 reducing their positions, and 16 closing their positions.
285% more call options, than puts
Call options by funds: $21.7M | Put options by funds: $5.64M
125% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 16
44% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 16
39% more capital invested
Capital invested by funds: $119M → $166M (+$46.9M)
7% more funds holding
Funds holding: 94 → 101 (+7)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$2.35M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$1.07M |
| 3 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$899K |
| 4 |
FI
Fosun International
Hong Kong,
China
|
+$805K |
| 5 |
BlackRock
New York
|
+$368K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$11.4M |
| 2 |
PC
Polar Capital
London,
United Kingdom
|
-$8.88M |
| 3 |
Millennium Management
New York
|
-$5.03M |
| 4 |
PA
Perceptive Advisors
New York
|
-$4.27M |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$644K |
AVEO Hedge Fund Activity: Q3 2018 in Review
101 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q3 2018, worth a combined $166M — up 39% from $119M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new AVEO positions and 16 closed out — a net gain of 7 holders — while 36 added to existing stakes and 16 trimmed.
The largest buyer was NEA Management Company, adding an estimated $2.35M. The largest seller was RA Capital Management, exiting entirely with an estimated $11.4M sold.
- 101 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q3 2018, up from 94 in Q2 2018.
- Funds reported $166M of AVEO Pharmaceuticals, Inc. stock for Q3 2018, up 39% quarter-over-quarter.
- 23 funds opened new AVEO Pharmaceuticals, Inc. positions in Q3 2018 and 16 closed out, a net change of +7 holders.
- The largest AVEO Pharmaceuticals, Inc. buyer in Q3 2018 was NEA Management Company, an estimated $2.35M added.
- The largest AVEO Pharmaceuticals, Inc. seller in Q3 2018 was RA Capital Management, an estimated $11.4M sold.
Based on aggregated 13F filings for Q3 2018.